Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Safer Transfusions In The Age Of Aids


Developments to Watch

SAFER TRANSFUSIONS IN THE AGE OF AIDS

While blood safety has greatly improved in recent years, current testing still cannot completely eliminate the chance that the virus that causes AIDS will be transmitted during a transfusion. But researchers at the New York Blood Center and New York University Medical Center say recent lab experiments have found that the antiviral compound hypericin is able to inactivate completely HIV in whole-blood supplies with no adverse effects on blood chemistry. VIMRx Pharmaceuticals Inc. in Stamford, Conn., which makes hypericin, says the compound is being tested to determine if it can also inactivate a broad range of other blood-borne viruses, such as hepatitis and cytomegalovirus, which can cause severe disease in newborns. Phase I trials have already shown hypericin to be safe in humans when transmitted intravenously, and VIMRx says it plans to apply for Food & Drug Administration licensing in 1995.EDITED BY CATHERINE ARNST


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus